Shots:

• The designation is based on interim results from the P-Ib M15-531 study evaluating Venclexta + azacitidine in naïve patients with previously untreated higher-risk MDS
• The primary objectives of the study are to assess the safety- Pk and determine the RP2D and dosing schedule of Venclexta in combination with azacitidin
• Venclexta is a novel inhibitor of BCL-2 protein- jointly developed & commercialized by Genentech & Abbvie in the US & commercialized by AbbVie outside of the US. The therapy is also approved in the US & EU in combination with Rituxan for the treatment of CLL & in combination with Gazyva for the treatment of patients with previously untreated CL

  | Ref: Businesswire | Image: Center for Health Journalism